Barry Labinger - 04 Aug 2021 Form 4 Insider Report for Checkmate Pharmaceuticals, Inc.

Role
President and CEO, Director
Signature
/s/ Kleem Chaudhary, attorney-in-fact
Issuer symbol
N/A
Transactions as of
04 Aug 2021
Net transactions value
$0
Form type
4
Filing time
06 Aug 2021, 16:05:17 UTC
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CMPI Stock Option (Right to Buy) Award $0 +85,950 $0.000000 85,950 04 Aug 2021 Common Stock 85,950 $5.09 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to such option vest and become exercisable on August 4, 2022 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.